This is an expanded access designed to provide access to apixaban for eligible participants.
Drug: Apixaban
Administered as directed by treating physician
Other Name: Eliquis
Inclusion Criteria: - Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention - Previously participated in the CV185-362 study and was on apixaban for 1 year or until treatment was no longer required
Exclusion Criteria: - Weight less than 5 kg or greater than 35 kg
Other inclusion/exclusion criteria apply
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104
Investigator: Andrew Glatz, Site 0001
Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb